Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial

BACKGROUND: Eptinezumab, an anti-calcitonin gene-related peptide monoclonal antibody recently approved in the United States for preventive treatment of migraine in adults, was found to be well tolerated in double-blind, placebo-controlled studies in patients with episodic and chronic migraine. The o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudrow, David, Cady, Roger K., Allan, Brent, Pederson, Susan M., Hirman, Joe, Mehta, Lahar R., Schaeffler, Barbara A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977171/
https://www.ncbi.nlm.nih.gov/pubmed/33740902
http://dx.doi.org/10.1186/s12883-021-02123-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977171/
https://www.ncbi.nlm.nih.gov/pubmed/33740902
http://dx.doi.org/10.1186/s12883-021-02123-w

Ejemplares similares